Is ADMA Biologics, Inc. overvalued or undervalued?

As of 6 August 2025, the valuation grade for ADMA Biologics, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued at this time, with a P/E ratio of 24, a Price to Book Value of 13.18, and an EV to EBITDA ratio of 30.78. Compared to its peers, ADMA's P/E ratio of 18.56 suggests it is relatively in line with the industry, while Protagonist Therapeutics, Inc. is considered very expensive with a P/E of 67.18.
In terms of performance, ADMA Biologics has shown significant long-term returns, with a 3-year return of 509.81% compared to the S&P 500's 70.41%, though it has underperformed in the shorter term, with a 1-year return of -16.36 against the S&P 500's 17.14. This disparity in returns highlights the volatility and potential risk associated with the stock, reinforcing the conclusion that it is fairly valued at present.